Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Leveraging mouse models and retinal organoids to optimize a gene therapy for IMPG2-associated retinal degeneration

Award Number: R01EY037934
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

Leveraging mouse models and retinal organoids to optimize a gene therapy for IMPG2-associated retinal degeneration - PROJECT SUMMARY IMPG2 is a crucial extracellular matrix protein for maintaining photoreceptor structure and function. Mutations in IMPG2 are linked to two forms of visual impairment: juvenile-onset rod-cone dystrophy and adult-onset vitelliform macular dystrophy. While no treatment currently exists, packaging IMPG2 amino acid sequences into adeno-associated viruses (AAVs) offers promise for a sight-preserving therapy. We recently generated human retinal organoid (RO) and mouse models to enable us to rapidly engineer a gene augmentation therapy for IMPG2-associated retinal dystrophy (RD). The retinal organoids (ROs), grown from either patient-derived (human) induced pluripotent stem cells (hiPSCs) or gene-edited embryonic stem cells (hESCs), recapitulate the lack of photoreceptor outer segments observed in advanced IMPG2-RD. This fully penetrant phenotype provides a biomarker for assessing functional IMPG2 expression after AAV-mediated gene transfer. Although patient-derived ROs are tractable in vitro models of clinical relevance, their use in assessing viral vector designs for gene therapy development is best complemented by in vivo assessment of safety and efficacy in animal models. Accordingly, we will assess therapeutic safety and efficacy using the Impg2-knockout (KO) model mice, as these mice exhibit gliosis, subretinal deposits, photoreceptor degeneration, retinal detachment, and reduced electroretinogram (ERG) responses that are similar to the human condition. Here, we will accelerate a preclinical program to test our central hypothesis that gene augmentation can prevent retinal pathology in an IMPG2-RD mouse model and patient-derived ROs. To lay the groundwork for a clinical IMPG2 gene therapy, we will complete the following Aims: (1) Use Impg2-KO mice to define endpoints for preclinical trials, (2) optimize a gene therapy viral vector design using Impg2-KO mice and IMPG2 patient-derived and gene-edited ROs, and (3) establish preclinical gene therapy safety and efficacy in Impg2-KO mice. Synergistically employing mouse models and human ROs will accelerate the development of a gene therapy that will meaningfully improve the lives of individuals with IMPG2-RD. More broadly, this work will demonstrate the power of a dual-model platform to advance safe and effective therapeutics with high predictive value for treating inherited retinal disorders.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $603,053 )
2026	2026	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Vision Research	000	1	4/17/2026	NEW	$603,053
														Subtotal = $603,053

Grand Total All Awards = $603,053

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Leveraging mouse models and retinal organoids to optimize a gene therapy for IMPG2-associated retinal degeneration

Award Number: R01EY037934

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer